Tyrosine

Tyrosine

SCHEMBL1908048

NC(Cc1ccc(O)cc1)C(=O)O.Oc1ccccc1

nearest known ligand 0.89

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 4/20 0.89
▸ PTGS1 P23219 2/20 0.75
▸ ALPI P09923 1/20 0.75
▸ PKM P14618 1/20 0.75
▸ XIAP P98170 1/20 0.75
▸ GRIA2 P42262 1/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ USP2 O75604 1/20 0.59
▸ EGFR P00533 1/20 0.59
▸ LCK P06239 1/20 0.59
▸ FYN P06241 1/20 0.59
▸ ADORA3 P0DMS8 1/20 0.59
▸ ALOX15 P16050 1/20 0.59
▸ HTR2A P28223 1/20 0.59
▸ PTGS2 P35354 1/20 0.59
▸ RECQL P46063 1/20 0.59
▸ HIF1A Q16665 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ HDAC8 Q9BY41 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tyrosine SCHEMBL28900255 1.00 SLC7A5 (0.89) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL1908049 1.00 SLC7A5 (0.89) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL28713124 0.96 SLC7A5 (0.83) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL5699043 0.96 SLC7A5 (0.89) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL27641183 0.96 SLC7A5 (0.89) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL1003558 0.96 SLC7A5 (0.89) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL5699039 0.96 SLC7A5 (0.89) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL133206 0.96 SLC7A5 (0.89) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL28244030 0.96 SLC7A5 (0.89) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL18222727 0.96 SLC7A5 (0.89) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021125352-A1 METHOD FOR SYNTHESIZING CELOSIANIN II, METHOD FOR SYNTHESIZING BETAXANTHIN, AMYLOID-β POLYMERIZATION INHIBITOR OR THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALZHEIMER'S DISEASE, AMYLOID PEPTIDE AGGREGATION INHIBITOR, AND HIV-1 PROTEASE ACTIVITY INHIBITOR 森 正之 2021-06-24 — — WO claimed
CN-107121427-B Reagent for detecting tyrosine phenol metabolites in human urine and preparation method thereof 朱建华 2020-06-16 — — CN claimed
CN-107084977-B Reagent for detecting tyrosine phenol metabolites in urine and product thereof 浙江欣叶健康管理有限公司 2020-02-18 — — CN claimed
CN-109281166-A A kind of protein fibre antibiotic finishing method based on enzymatic graft copolymerization 江南大学 2019-01-29 — — CN claimed
CN-108922630-A A kind of method and device pushing knowledge 上海森亿医疗科技有限公司 2018-11-30 — — CN claimed
CN-108715827-A The extracellular expression of tyrosine phenol lyase and its application 鲁东大学 2018-10-30 — — CN claimed
CN-107586797-A The method that one pot of enzyme process prepares levodopa 长兴制药股份有限公司 2018-01-16 — — CN claimed
CN-107325996-A A kind of tyrosine phenol lyase engineering bacteria and its construction method and application 浙江绿创生物科技有限公司 2017-11-07 — — CN claimed
CN-106565425-A Method for recycling catechol and levodopa from levodopa mother liquor 浙江华海药业股份有限公司 2017-04-19 — — CN claimed
CN-106226299-A For detecting the test kit of tyrosine phenol metabolism thing 李永福 2016-12-14 — — CN claimed
CN-104949967-B The kit of tyrosine phenol metabolism thing in detection human urine 杭州欣叶生物科技有限公司 2016-08-24 — — CN claimed
CN-105203537-A Urine testing reagent for tyrosine phenol metabolin HANGZHOU XIN YE BIOLOG TECHNOLOGY CO LTD 2015-12-30 — — CN claimed
CN-105044100-A Kit for detecting tyrosine phenolic metabolite in human urine HANGZHOU XIN YE BIOLOG TECHNOLOGY CO LTD 2015-11-11 — — CN claimed
CN-104949967-A Kit for detecting tyrosine phenol metabolites in human urine HANGZHOU XIN YE BIOLOG TECHNOLOGY CO LTD 2015-09-30 — — CN claimed
US-12624070-B2 High contrast photoconvertible fluorescent proteins and methods of use BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2026-05-12 — — US disclosed
WO-2025090774-A1 CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE SEAGEN INC. (US) 2025-05-01 — — WO disclosed
WO-2024148312-A1 COMPOSITIONS, SYSTEMS, AND METHODS FOR AMINO ACID SYNTHESIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-07-11 — — WO disclosed
EP-0359399-A1 Process for the enzymatic production of dipeptides CARLBIOTECH LTD. A/S (DK) 1990-03-21 — — EP disclosed
WO-1990001555-A1 A PROCESS FOR ENZYMATIC PRODUCTION OF DIPEPTIDES OR STRUCTURALLY RELATED COMPOUNDS CARLBIOTECH LTD. A/S (DK) 1990-02-22 — — WO disclosed
CN-87106781-A Process for preparing small pieces of plant products from viscous powder — 1988-06-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12624070-B2 High contrast photoconvertible fluorescent proteins and methods of use SET, UPF1, IK SLC7A5 191/4885PTGS1 3930/4885ALPI 4170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback